MRI abnormalities in children following sequential chemotherapy, hyperfractionated accelerated radiotherapy and high-dose thiotepa for high-risk primitive neuroectodermal tumours of the central nervous system

被引:9
|
作者
Thust, Stefanie C. [1 ,3 ]
Blanco, Esther [2 ]
Michalski, Antony J. [2 ]
Chong, W. K. [1 ]
Gaze, Mark N. [2 ,3 ]
Phipps, Kim [2 ]
Mankad, Kshitij [1 ]
机构
[1] Great Ormond St Hosp Children NHS Fdn Trust, Dept Paediat Neuroradiol, London, England
[2] Great Ormond St Hosp Children NHS Fdn Trust, Dept Paediat Oncol, London, England
[3] Univ Coll London Hosp NHS Fdn Trust, Dept Oncol, London, England
关键词
cerebral primitive neuroectodermal tumour; chemotherapy; medulloblastoma; paediatrics; radiation oncology; thiotepa; WHITE-MATTER; BRAIN-TUMORS; RADIATION-THERAPY; CRANIOSPINAL RADIOTHERAPY; MEDULLOBLASTOMA; CHILDHOOD; PSEUDOPROGRESSION; SURVIVORS; INJURY; TRIAL;
D O I
10.1111/1754-9485.12232
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction: Intensive postsurgical therapies have improved survival in children with primitive neuroectodermal tumour, but there is concern that the combination of chemotherapy and radiotherapy may result in a compound injury to normal brain. The purposes of this analysis were to characterise what types of imaging abnormalities occur, identify risk factors and explore how treatment-related changes may be distinguished from tumour. Method: One hundred fifty-three MRI studies in 14 children treated with sequential chemotherapy, hyperfractionated accelerated radiotherapy and high-dose thiotepa were retrospectively analysed at a paediatric national referral centre. Results: We observed 11 episodes of new focal enhancing lesions, 5 of which were transient and judged to be treatment related. In addition, 7/14 (50%) of children demonstrated moderate to severe brain volume loss featuring a leukodystrophy pattern. Conclusion: Treatment-related brain MRI abnormalities occurred frequently in this series with a risk of misdiagnosis as tumour. A proportion of patients suffer generalised white matter injury, which has not been appreciated as a side effect of this particular therapy.
引用
收藏
页码:683 / 690
页数:8
相关论文
共 50 条
  • [31] High-dose chemotherapy containing topotecan, thiotepa and carboplatin with autologous stem cell rescue for high-risk medulloblastorna
    Muramatsu, H
    Matsumoto, K
    Kato, K
    Inao, S
    BONE MARROW TRANSPLANTATION, 2005, 35 : S390 - S390
  • [32] High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors
    V Papadakis
    IJ Dunkel
    LD Cramer
    E Kramer
    E Papadopoulos
    S Goldman
    RJ Packer
    M Willoughby
    D Baker
    J Garvin
    S Strandjord
    P Coccia
    AM Kaplan
    M Klemperer
    JL Finlay
    Bone Marrow Transplantation, 2000, 26 : 153 - 160
  • [33] SEQUENTIAL HIGH-DOSE CHEMOTHERAPY (HDCT) AND IMMUNOTHERAPY IN THE ADJUVANT TREATMENT OF HIGH-RISK BREAST CANCER
    Recchia, F.
    Saggio, G.
    Cesta, A.
    Rea, S.
    ANNALS OF ONCOLOGY, 2004, 15 : 21 - 22
  • [34] The Result of High-Dose Chemotherapy with Autologous Stem Cells Transplantation of the Central Nervous System Tumor in Children
    Prihodko, I.
    Klymnyuk, G.
    Pavlyk, S.
    Shaida, E.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S555 - S555
  • [35] Pharmacokinetics of thiotepa and mitoxantrone in high-dose chemotherapy with autologous stem cell support of patients with high-risk breast cancer
    Wolkewitz, B
    Hilger, RA
    Skorzec, M
    Markus-Matulla, A
    Mayer, S
    Steiniger, H
    Schneemann, H
    Seeber, S
    Scheulen, ME
    BONE MARROW TRANSPLANTATION, 1998, 22 : S60 - S64
  • [36] A pilot trial of tandem autologous peripheral blood progenitor cell transplantation following high-dose thiotepa and carboplatin in children with poor-risk central nervous system tumors
    Ozkaynak, M
    Sandoval, C
    Levendoglu-Tugal, O
    Jayabose, S
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2004, 21 (07) : 635 - 645
  • [37] A PHASE II STUDY OF PRERADIOTHERAPY CHEMOTHERAPY FOLLOWED BY HYPERFRACTIONATED RADIOTHERAPY FOR NEWLY DIAGNOSED HIGH-RISK MEDULLOBLASTOMA/PRIMITIVE NEUROECTODERMAL TUMOR: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (CCG 9931)
    Allen, Jeffrey
    Donahue, Bernadine
    Mehta, Minesh
    Miller, Douglas C.
    Rorke, Lucy B.
    Jakacki, Regina
    Robertson, Patricia
    Sposto, Richard
    Holmes, Emi
    Vezina, Gilbert
    Muraszko, Karin
    Puccetti, Diane
    Prados, Michael
    Chan, Ka-Wah
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 74 (04): : 1006 - 1011
  • [38] Feasibility of an accelerated multi-cycle high-dose chemotherapy regimen including high-dose thiotepa for patients (Pts) with poor risk ovarian cancer (OC)
    Crown, J
    Chan, KM
    O'Leary, M
    Ballot, J
    King, T
    Murphy, J
    Lenehan, P
    Drumm, J
    McCarthy, D
    Fennelly, D
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S232 - S232
  • [39] Outcome after high-dose methotrexate and radiotherapy for primary central nervous system lymphoma
    Choi, J. H.
    Kim, I. H.
    Heo, D. S.
    Jung, H. W.
    EJC SUPPLEMENTS, 2009, 7 (02): : 501 - 501
  • [40] Outcome after High-dose Methotrexate and Radiotherapy in Primary Central Nervous System Lymphoma
    Choi, J.
    Kim, I.
    Heo, D.
    Jung, H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S254 - S254